Genetically Engineered Mouse Models Support a Major Role of Immune Checkpoint-Dependent Immunosurveillance Escape in B-Cell Lymphomas.

Szczegóły
Abstrakt

Tytuł:: Genetically Engineered Mouse Models Support a Major Role of Immune Checkpoint-Dependent Immunosurveillance Escape in B-Cell Lymphomas.
Autorzy:: Lemasson Q; UMR CNRS 7276/INSERM U1262 CRIBL, University of Limoges, Limoges, France.; Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.
Akil H; UMR CNRS 7276/INSERM U1262 CRIBL, University of Limoges, Limoges, France.; Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.
Feuillard J; UMR CNRS 7276/INSERM U1262 CRIBL, University of Limoges, Limoges, France.; Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.
Vincent-Fabert C; UMR CNRS 7276/INSERM U1262 CRIBL, University of Limoges, Limoges, France.; Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.
Źródło:: Frontiers in immunology [Front Immunol] 2021 May 25; Vol. 12, pp. 669964. Date of Electronic Publication: 2021 May 25 (Print Publication: 2021).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Review
Język:: English
Imprint Name(s):: Original Publication: [Lausanne : Frontiers Research Foundation]
MeSH Terms:: Tumor Escape*/drug effects
Tumor Escape*/genetics
Immune Checkpoint Proteins/*immunology
Lymphoma, B-Cell/*immunology
Tumor Microenvironment/*immunology
Animals ; Gene Expression Regulation, Neoplastic ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Proteins/genetics ; Immune Checkpoint Proteins/metabolism ; Immunotherapy ; Lymphoma, B-Cell/drug therapy ; Lymphoma, B-Cell/genetics ; Lymphoma, B-Cell/metabolism ; Mice, Transgenic ; Signal Transduction ; Tumor Microenvironment/genetics
References:: Science. 1999 Jul 30;285(5428):730-2. (PMID: 10426994)
Cell Commun Signal. 2019 Aug 5;17(1):89. (PMID: 31382969)
Semin Hematol. 1985 Jan;22(1):27-40. (PMID: 3155876)
Haematologica. 2017 May;102(5):883-894. (PMID: 28232371)
Eur J Immunol. 2010 Feb;40(2):494-504. (PMID: 19950185)
Nature. 2011 Feb 3;470(7332):115-9. (PMID: 21179087)
Cancer Res. 2017 Sep 15;77(18):5118-5128. (PMID: 28716895)
Blood. 2003 Aug 15;102(4):1389-96. (PMID: 12714493)
Leukemia. 2012 May;26(5):1122-7. (PMID: 22033491)
Oncogene. 2017 Feb 2;36(5):628-638. (PMID: 27452524)
Biophys J. 2018 Oct 2;115(7):1330-1343. (PMID: 30219287)
J Immunol Res. 2018 Apr 11;2018:1982423. (PMID: 29850620)
Blood. 2021 May 20;137(20):2785-2799. (PMID: 33232972)
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9701-9706. (PMID: 28831000)
Blood. 2011 Jan 13;117(2):563-74. (PMID: 20940416)
Hum Mol Genet. 2020 Jan 1;29(1):70-79. (PMID: 31600786)
Semin Cancer Biol. 2016 Aug;39:61-7. (PMID: 27503810)
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60. (PMID: 12011454)
J Clin Invest. 2018 Dec 3;128(12):5465-5478. (PMID: 30277471)
Hum Pathol. 2016 Aug;54:17-24. (PMID: 27045512)
Front Oncol. 2018 Mar 07;8:54. (PMID: 29564225)
Immunity. 2008 Apr;28(4):571-80. (PMID: 18394936)
Blood. 2019 May 23;133(21):2279-2290. (PMID: 30910787)
Blood. 2019 May 30;133(22):2401-2412. (PMID: 30975638)
Nature. 2002 Oct 17;419(6908):734-8. (PMID: 12384702)
Oncoimmunology. 2015 Jan 07;4(3):e990773. (PMID: 25949906)
Blood. 2015 Jul 9;126(2):203-11. (PMID: 25800048)
EMBO J. 1992 Nov;11(11):3887-95. (PMID: 1396582)
J Exp Med. 2000 Oct 2;192(7):1027-34. (PMID: 11015443)
J Immunol. 2012 Aug 1;189(3):1360-71. (PMID: 22730533)
Leukemia. 2011 Sep;25(9):1452-8. (PMID: 21606964)
Nature. 1983 Jul 14-20;304(5922):165-7. (PMID: 6602947)
Nat Immunol. 2000 Aug;1(2):119-26. (PMID: 11248803)
J Biochem. 1996 Nov;120(5):987-95. (PMID: 8982867)
Clin Cancer Res. 2017 Apr 1;23(7):1623-1626. (PMID: 27881581)
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5. (PMID: 18765795)
Immunol Rev. 2019 Mar;288(1):37-48. (PMID: 30874355)
Clin Dev Immunol. 2012;2012:925135. (PMID: 22474485)
Cell Mol Immunol. 2019 Apr;16(4):412-414. (PMID: 30635651)
J Clin Oncol. 2019 Feb 20;37(6):481-489. (PMID: 30620669)
Int J Mol Sci. 2020 May 31;21(11):. (PMID: 32486375)
Blood Cancer Discov. 2021 Jan;2(1):70-91. (PMID: 33447829)
Blood. 2016 May 19;127(20):2375-90. (PMID: 26980727)
Cell. 2012 Feb 17;148(4):739-51. (PMID: 22341446)
Blood. 2009 Nov 5;114(19):4158-68. (PMID: 19696203)
Cell Mol Immunol. 2019 Jun;16(6):621-624. (PMID: 30967638)
Leukemia. 2016 Mar;30(3):605-16. (PMID: 26500140)
Clin Cancer Res. 2013 Jul 1;19(13):3462-73. (PMID: 23674495)
Immunity. 2000 Jun;12(6):721-7. (PMID: 10894171)
J Immunol. 2019 May 1;202(9):2806-2816. (PMID: 30910862)
Eur J Immunol. 2015 Sep;45(9):2593-601. (PMID: 26151313)
Blood. 2000 Nov 15;96(10):3569-77. (PMID: 11071656)
J Immunol. 2019 Sep 15;203(6):1665-1674. (PMID: 31434708)
Nat Med. 1999 Dec;5(12):1365-9. (PMID: 10581077)
J Exp Med. 2008 Jun 9;205(6):1317-29. (PMID: 18490492)
Front Oncol. 2018 Sep 10;8:351. (PMID: 30250823)
Nature. 2017 Jan 18;541(7637):321-330. (PMID: 28102259)
J Immunol. 1998 Oct 1;161(7):3501-9. (PMID: 9759870)
Blood. 2015 Jul 9;126(2):212-21. (PMID: 25979947)
Blood. 2018 Jan 4;131(1):68-83. (PMID: 29118007)
Blood. 2016 Jun 2;127(22):2732-41. (PMID: 27048211)
Contributed Indexing:: Keywords: B-cell lymphoma; CTLA-4; MHC-II; NKG2D; PD-1/PD-L1; immune surveillance
Substance Nomenclature:: 0 (Immune Checkpoint Inhibitors)
0 (Immune Checkpoint Proteins)
Entry Date(s):: Date Created: 20210611 Date Completed: 20211020 Latest Revision: 20211020
Update Code:: 20240104
PubMed Central ID:: PMC8186831
DOI:: 10.3389/fimmu.2021.669964
PMID:: 34113345
: Czasopismo naukowe

Full Text Finder

These last 20 years, research on immune tumor microenvironment led to identify some critical recurrent mechanisms used in cancer to escape immune response. Through immune checkpoints, which are cell surface molecules involved in the immune system control, it is now established that tumor cells are able to shutdown the immune response. Due to the complexity and heterogeneity of Non Hodgkin B-cell Lymphomas (NHBLs), it is difficult to understand the precise mechanisms of immune escape and to explain the mitigated effect of immune checkpoints blockade for their treatment. Because genetically engineered mouse models are very reliable tools to improve our understanding of molecular mechanisms involved in B-cell transformation and, at the same time, can be useful preclinical models to predict immune response, we reviewed hereafter some of these models that highlight the immune escape mechanisms of NHBLs and open perspectives on future therapies.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Lemasson, Akil, Feuillard and Vincent-Fabert.)

Informacja